Questions? +1 (202) 335-3939 Login
Trusted News Since 1995
A service for global professionals · Thursday, May 29, 2025 · 817,252,234 Articles · 3+ Million Readers

Stratus Announces Publication of Stratus PRIME™ HSC Platform in the American Journal of Hematology

First-in-class approach enables the generation of transgene-free hematopoietic stem cells through mechanosensitive PIEZO1 activation

Stratus has an exclusive license to the intellectual property for the platform technology – Stratus Prime™

/EIN News/ -- CAMBRIDGE, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Stratus Therapeutics, Inc. (“Stratus”), a biotechnology company advancing on-demand hematopoietic stem cell (HSC) therapies, today announced the publication of its foundational platform technology in the American Journal of Hematology. The publication, titled PIEZO1 Activation-Mediated Generation of Transgene-Free Long-Term Hematopoietic Stem Cells (Am J Hematol. 2025; 100:963–979), presents research that underpins Stratus’ Prime™ platform to produce its Prime HSCs™ and Prime HPCs™, both of which are components of Stratus’ lead product candidate, ST-101.

The research, conducted at Brigham and Women’s Hospital and exclusively licensed to Stratus, establishes a novel method for generating long-term reconstituting, transgene-free HSCs, or Prime HSCs™, from both embryonic hemogenic endothelial cells and human pluripotent stem cells (hPSCs), through targeted activation of the PIEZO1 mechanosensitive ion channel.

“The publication marks a critical step in validating the scientific foundation of the Stratus Prime™ platform,” said Avanish Vellanki, President and CEO of Stratus. “This approach opens the door to off-the-shelf, fully immune compatible stem cell therapies — a major advance for patients who currently face delays and debilitating side effects like Graft-versus-Host Disease (GvHD).”

The American Journal of Hematology paper highlighted the following key findings:

  • Significance of PIEZO1’s role in the generation of long-term reconstituting hematopoietic stem cells (Prime HSCs™) from embryonic hemogenic endothelial cells and human pluripotent stem cells (hPSCs)
  • Parameters required for mechanosensitive stimulation of PIEZO1 to generate Prime HSCs™
  • Pharmacological recapitulation of PIEZO1 activation and generation of Prime HSCs™ in the absence of mechanical stimulation, arising from the ventral wall of the dorsal aorta
  • Stable engraftment of transgene-free Prime HSCs™ in immunocompromised mice
  • Durable production of blood and immune cells from Prime HSCs™, using well-accepted lineage cell markers

About Stratus Therapeutics
Stratus Therapeutics is redefining regenerative medicine with Stratus Prime™ — a platform for full hematopoietic system renewal, on demand. Our proprietary product, ST-101, includes both hematopoietic stem cells (Prime HSCs™) and hematopoietic progenitor cells (Prime HPCs™) to drive durable, long-term engraftment with full hematopoietic system restoration, while supporting near-term immune reconstitution. ST-101 is uniquely engineered to deliver a high proportion of Prime HSCs™ in the absence of T-cells, positioning it as a next-generation allogeneic graft, but with immediate availability. ST-101 aims to offer enhanced engraftment outcomes while diminishing the risk of graft-versus-host disease (GvHD). As an off-the-shelf therapy with full HLA immune compatibility, ST-101 aims to eliminate the search associated with finding donors and potentially mitigate the challenges of conventional conditioning regimens. Stratus Therapeutics hopes to position ST-101 as a scalable path to curative blood and immune system replacement. Additional information can be found at www.stratustx.com.

Company Contact
ir@stratustx.com

Investor Contact
Dan Ferry
LifeSci Advisors
+1.617.430.7576
Daniel@lifesciadvisors.com


Primary Logo

Powered by EIN News

Distribution channels: Media, Advertising & PR, Technology ...

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Submit your press release